These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33911888)

  • 1. Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018.
    Deng Y; Zhao Q; Gong R
    Diabetes Metab Syndr Obes; 2021; 14():1751-1761. PubMed ID: 33911888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.
    Cen C; Fan Z; Ding X; Tu X; Liu Y
    Sci Rep; 2024 Jun; 14(1):12645. PubMed ID: 38825630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease: A cross-sectional study.
    Badawi R; Fahmy Abou Taira NS; Hasby SE; Elkhalawany W; Elrefaey W; Ahmed Khalf N; Ibrahim Okda H
    Saudi Med J; 2024 Oct; 45(10):1034-1040. PubMed ID: 39379109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
    Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
    Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
    Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
    J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.
    Tang LJ; Sun DQ; Song SJ; Yip TC; Wong GL; Zhu PW; Chen SD; Karsdal M; Leeming DJ; Jiang P; Wang C; Chen Q; Byrne CD; Targher G; Eslam M; George J; Wong VW; Zheng MH
    Liver Int; 2024 May; 44(5):1129-1141. PubMed ID: 38426611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
    Wei S; Song J; Xie Y; Huang J; Yang J
    JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
    Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
    Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perirenal Fat Thickness is Associated with Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus.
    Yang J; Li CW; Zhang JR; Qiu H; Guo XL; Wang W
    Diabetes Metab Syndr Obes; 2023; 16():1953-1965. PubMed ID: 37405319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperuricemia as an independent risk factor for metabolic dysfunction-associated fatty liver disease in nonobese patients without type 2 diabetes mellitus.
    Liu J; Wang C; Wang YT; Liu JX; Zhou TH; Yao SK; Chen G
    Am J Physiol Endocrinol Metab; 2023 Jul; 325(1):E62-E71. PubMed ID: 37285598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
    Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
    Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
    Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH
    Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian Misalignment Rather Than Sleep Duration is Associated with MAFLD: A Population-Based Propensity Score-Matched Study.
    Weng Z; Ou W; Huang J; Singh M; Wang M; Zhu Y; Kumar R; Lin S
    Nat Sci Sleep; 2021; 13():103-111. PubMed ID: 33542668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between self-reported snoring and metabolic-associated fatty liver disease: A cross-sectional analysis of the NHANES 2017-2018.
    Wang Y; Shen R; Ge J
    Sleep Med; 2023 Jan; 101():414-420. PubMed ID: 36516525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017-2018.
    Yang Z; Gong D; He X; Huang F; Sun Y; Hu Q
    Front Nutr; 2023; 10():1113789. PubMed ID: 36860686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study.
    Akahane T; Akahane M; Namisaki T; Kaji K; Moriya K; Kawaratani H; Takaya H; Sawada Y; Shimozato N; Fujinaga Y; Furukawa M; Kitagawa K; Ozutsumi T; Tsuji Y; Kaya D; Mitoro A; Yoshiji H
    J Clin Med; 2020 May; 9(6):. PubMed ID: 32481684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics of lean metabolic-associated fatty liver disease and the impact of concurrent diabetes mellitus.
    Cheng YM; Wang SW; Wang CC; Kao JH
    Tzu Chi Med J; 2024; 36(4):425-432. PubMed ID: 39421499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.